Early clinical milestone unlikely to move shares near term; focus on interim safety data after first 5 patients for potential catalyst. Historical stock reaction to similar updates has been weak.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $1.02entry
- T+1 · 6mo ago 0.00%α −0.83% · $1.02
- T+5 · 6mo ago 0.00%α −1.50% · $1.02
- T+20 · 6mo ago 0.00%α −3.14% · $1.02
- T+60 · 4mo ago +152.94%α +149.11% · $2.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau announced the first patient treated in Italy with its Alpha DaRT therapy for pancreatic cancer, a feasibility and safety study at the University of Verona's Pancreas Institute. The milestone expands the company's global pancreatic cancer program but represents an early-stage clinical update with no near-term revenue implications.
Key Facts
- First Alpha DaRT pancreatic cancer patient treated in Italy under protocol CTP-PANC-03
- Study plans to enroll up to 15 patients with locally advanced pancreatic cancer at a single center
- First Alpha DaRT pancreatic protocol to permit both endoscopic ultrasound (EUS) and percutaneous delivery
- Follows first European patient treated in April 2026 in France's ACAPELLA trial and ongoing U.S. IMPACT trial
Financial Impact
No financial data provided; zero-revenue clinical-stage company with no near-term commercialization impact
Risk Factors
- Pancreatic cancer trials have high failure rate; feasibility/safety data may not translate to efficacy
- Company has significant operating losses and requires additional funding; dilution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-053086 |
| Document: ea0289554-6k_alphatau.htm | 0001213900-26-053086 |
| Document: 0001213900-26-053086-index-headers.html | 0001213900-26-053086 |
| Document: 0001213900-26-053086-index.html | 0001213900-26-053086 |
| Document: 0001213900-26-053086.txt | 0001213900-26-053086 |
Track record
14 reports on DRTSW
9 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 9 of 9 went positive at some point.
Filters
- Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
- Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
- May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
- May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 7, 202627w ago 6-K Neutral 3/10 Viewing Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
- May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
- May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers